Evaluación de la nitazoxanida en dosis única y por tres días en parasitosis intestinal

Belkind-Valdovinos, Uri; Belkind‐Gerson, Jaime; Sánchez-Francia, Domingo; Espinoza-Ruiz, Mónica Marcela; Lazcano‐Ponce, Eduardo

doi:10.1590/s0036-36342004000400008

Cited by 17 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The English translation says that a sample of adult patients infected with E histolytica was divided into 2 groups but does not mention randomizationArredondo 1993Ineligible study population: RCT that compared medical treatment with medical treatment plus liver puncture in patients with amoebic liver abscessAtias 1972Not an RCTBakshi 1978Review of 17 RCTs conducted in India and comparing tinidazole with metronidazole over a 2‐year periodBanerjee 1976Not an RCTBaranski 1966Not an RCTBarroso 1969Not an RCTBassily 1987Not an RCTBelkind 2004Ineligible study population: asymptomatic children positive for intestinal helminths or protozoaBezjak 1964Not an RCTBhatia 1998Ineligible study population: RCT comparing metronidazole with secnidazole in treating patients with amoebic liver abscessBiagi 1966Wrong intervention: RCT comparing clefamide with placebo given not as treatment but as chemoprophylaxis for intestinal amoebiasis among asymptomatic carriers of E histolytica. Both the primary trial and the subsidiary trial by Biagi are probably duplicate publications of the same study because the 2 trials are similar in all aspectsBiagi 1978Not an RCTBlanc 1965Not an RCT.…”

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

Antiamoebic drugs for treating amoebic colitis

Gonzales

Dans

Sio‐Aguilar

2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Infection with the protozoan Entamoeba histolytica is common in low‐ and middle‐income countries, and up to 100,000 people with severe disease die every year. Adequate therapy for amoebic colitis is necessary to reduce illness, prevent development of complicated disease and extraintestinal spread, and decrease transmission. Objectives To evaluate antiamoebic drugs for treating amoebic colitis. Search methods We searched the available literature up to 22 March 2018. We searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, m RCT, and conference proceedings. We contacted individual researchers, organizations, and pharmaceutical companies, and we checked reference lists. Selection criteria Randomized controlled trials of antiamoebic drugs given alone or in combination, compared with placebo or another antiamoebic drug, for treating adults and children with a diagnosis of amoebic colitis. Data collection and analysis Two review authors independently assessed the eligibility and methodological quality of trials and extracted and analysed the data. We calculated clinical and parasitological failure rates and rates of relapse and adverse events as risk ratios (RRs) with 95% confidence intervals (CIs), using a random‐effects model. We determined statistical heterogeneity and explored possible sources of heterogeneity using subgroup analyses. We carried out sensitivity analysis by using trial quality to assess the robustness of reported results. Main results In total, 41 trials (4999 participants) met the inclusion criteria of this review. In this update, we added four trials to the 37 trials included in the first published review version. Thirty trials were published over 20 years ago. Only one trial used adequate methods of randomization and allocation concealment, was blinded, and analysed all randomized participants. Only one trial used an E histolytica stool antigen test, and two trials used amoebic culture. Tinidazole may be more effective than metronidazole for reducing clinical failure (RR 0.28, 95% CI 0.15 to 0.51; 477 participants, eight trials; low‐certainty evidence) and is probably associated with fewer adverse events (RR 0.65, 95% CI 0.46 to 0.92; 477 participants, 8 trials; moderate‐certainty evidence). Compared with metronidazole, combination therapy may result in fewer parasitological failures (RR 0.36, 95% CI 0.15 to 0.86; 720 participants, 3 trials; low‐certainty evidence), but we are uncertain which combination is more effective than another. Evidence is insufficient to allow conclusions regarding the efficacy of other antiamoebic drugs. Authors' conclusions Compared with metronidazole, tinidazole may be more effective in reducing clinical failur...

show abstract

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

Antiamoebic drugs for treating amoebic colitis

Gonzales

Dans

Sio‐Aguilar

2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Nitazoxanide is a synthetic derivative drug of salicylamide, used as a broad-spectrum antiparasitic agent with proven effectiveness in protozoal infections and worms [9,[39][40][41]. It is approved for infections by parasites such as G. lamblia and Asacarididos in human patients [13,15]; it is considered an extremely safe pediatric drug [28].…”

Section: Nitazoxanidementioning

confidence: 99%

Pharmacological Treatment of Giardiasis

Díaz¹

2017

Current Topics in Giardiasis

View full text Add to dashboard Cite

Giardiasis is a disease caused for a myoflagellate protozoan known as Giardia duodenalis, of which varieties have been described and whose morphological characteristics are identical to other species such as G. lamblia and G. intestinalis; considered for various authors as the same species, this protozoan parasites several domestic species including man, but has important relevance in the canine and feline species, due to their zoonotic potential. In recent years, the number of cases of canine and feline giardiasis has increased, not only because it is treated of a cosmopolitan parasite, which is closely related to unsanitary conditions, but also because the conventional treatments for its control and eradication have shown resistance phenomena. It is for this reason and being a parasite of potential zoonotic risk that at present pharmacological tests have been developed in the search for new alternatives for the treatment of giardiasis, especially in the canine and feline species as mentioned earlier.

show abstract

“…1 Para apoyar esta conclusión, damos a conocer los resultados sobre los efectos adversos de nitazoxanida, que fue utilizada en una campaña masiva de desparasitación en Minatitlán, Veracruz.…”

Section: Nitazoxanida: Reacciones Adversasunclassified

“…Desde las primeras publicaciones que realizamos sobre nitazoxanida habíamos considerado que no era la panacea en el tratamiento de las parasitosis intestinales, ya que había evidencia clí-nica de que el fármaco ocasionaba serias reacciones adversas y que su eficacia no era mayor a la de otros antiparasitarios que producen menos reacciones secundarias y son más baratos. [2][3][4] Otras publicaciones científicas han demostrado estos mismos hallazgos y, 1,5,6 además, Stockis y colaboradores encontraron reacciones adversas importantes en adultos sanos voluntarios. 7,8 Podemos concluir que la nitazoxanida ocasiona reacciones adversas frecuentes y severas, por lo cual debe ser usada con precaución y debe evitarse su uso en las campañas masivas de desparasitación.…”

Section: Minatitlán Veracruz México 2002unclassified